Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This is a phase II study in patients with seasonal allergic rhinitis (SAR) and will compare
the effect versus placebo of two different oral doses of BLX-028914 in an allergen challenge
model. BLX-028914, a selective phosphodiesterase-4 (PDE4) inhibitor with a promising safety
profile,is currently under development for treatment of airway diseases by Orexo AB, Sweden.
The aim of this study is to compare the effect, safety and tolerability of 14 days treatment
with BLX-0289014 in patients with SAR in an allergen challenge model versus placebo.